List of G1 Therapeutics patents

Patents where

Current Assignee

Name

G1 Therapeutics

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 11364222 Combination therapy for treatment of cancer	Patent 11364222 was granted and assigned to G1 Therapeutics on June, 2022 by the United States Patent and Trademark Office.		G1 Therapeutics	United States Patent and Trademark Office	11364222	June 21, 2022
‌ US Patent 10076523 HSPC-sparing treatments for RB-positive abnormal cellular proliferation	Patent 10076523 was granted and assigned to G1 Therapeutics on September, 2018 by the United States Patent and Trademark Office.	G1 Therapeutics	G1 Therapeutics	United States Patent and Trademark Office	10076523	September 18, 2018
‌ US Patent 11040042 Transient protection of normal cells during chemotherapy	Patent 11040042 was granted and assigned to G1 Therapeutics on June, 2021 by the United States Patent and Trademark Office.	G1 Therapeutics	G1 Therapeutics	United States Patent and Trademark Office	11040042	June 22, 2021
‌ US Patent 11395821 Treatment of EGFR-driven cancer with fewer side effects		G1 Therapeutics	G1 Therapeutics	United States Patent and Trademark Office	11395821	July 26, 2022
‌ US Patent 11643416 Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors	Patent 11643416 was granted and assigned to G1 Therapeutics on May, 2023 by the United States Patent and Trademark Office.	G1 Therapeutics	G1 Therapeutics	United States Patent and Trademark Office	11643416	May 9, 2023
‌ US Patent 11446295 Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat Rb-positive tumors	Patent 11446295 was granted and assigned to G1 Therapeutics on September, 2022 by the United States Patent and Trademark Office.	G1 Therapeutics	G1 Therapeutics	United States Patent and Trademark Office	11446295	September 20, 2022
‌ US Patent 11529352 Preservation of immune response during chemotherapy regimens	Patent 11529352 was granted and assigned to G1 Therapeutics on December, 2022 by the United States Patent and Trademark Office.	G1 Therapeutics	G1 Therapeutics	United States Patent and Trademark Office	11529352	December 20, 2022
‌ US Patent 11357779 G1T38 superior dosage regimes	Patent 11357779 was granted and assigned to G1 Therapeutics on June, 2022 by the United States Patent and Trademark Office.	G1 Therapeutics	G1 Therapeutics	United States Patent and Trademark Office	11357779	June 14, 2022
‌ US Patent 11629150 Synthesis of N-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines	Patent 11629150 was granted and assigned to G1 Therapeutics on April, 2023 by the United States Patent and Trademark Office.	G1 Therapeutics	G1 Therapeutics	United States Patent and Trademark Office	11629150	April 18, 2023
‌ US Patent 10085992 Transient protection of normal cells during chemotherapy	Patent 10085992 was granted and assigned to G1 Therapeutics on October, 2018 by the United States Patent and Trademark Office.	G1 Therapeutics	G1 Therapeutics	United States Patent and Trademark Office	10085992	October 2, 2018
‌ US Patent 9260442 Lactam kinase inhibitors	Patent 9260442 was granted and assigned to G1 Therapeutics on February, 2016 by the United States Patent and Trademark Office.		G1 Therapeutics	United States Patent and Trademark Office	9260442	February 16, 2016
‌ US Patent 10413547 Treatment of Rb-negative tumors using topoisomerase with cyclin dependent kinase 4/6 inhibitors	Patent 10413547 was granted and assigned to G1 Therapeutics on September, 2019 by the United States Patent and Trademark Office.	G1 Therapeutics	G1 Therapeutics	United States Patent and Trademark Office	10413547	September 17, 2019
‌ US Patent 10618905 Pyrimidine-based compounds for the treatment of cancer		G1 Therapeutics	G1 Therapeutics	United States Patent and Trademark Office	10618905	April 14, 2020
‌ US Patent 10988479 Morphic forms of trilaciclib and methods of manufacture thereof	Patent 10988479 was granted and assigned to G1 Therapeutics on April, 2021 by the United States Patent and Trademark Office.	G1 Therapeutics	G1 Therapeutics	United States Patent and Trademark Office	10988479	April 27, 2021
‌ US Patent 10189849 CDK inhibitors	Patent 10189849 was granted and assigned to G1 Therapeutics on January, 2019 by the United States Patent and Trademark Office.	G1 Therapeutics	G1 Therapeutics	United States Patent and Trademark Office	10189849	January 29, 2019
‌ US Patent 10434104 HSPC-sparing treatments for Rb-positive abnormal cellular proliferation	Patent 10434104 was granted and assigned to G1 Therapeutics on October, 2019 by the United States Patent and Trademark Office.	G1 Therapeutics	G1 Therapeutics	United States Patent and Trademark Office	10434104	October 8, 2019
‌ US Patent 10189850 CDK inhibitors	Patent 10189850 was granted and assigned to G1 Therapeutics on January, 2019 by the United States Patent and Trademark Office.	G1 Therapeutics	G1 Therapeutics	United States Patent and Trademark Office	10189850	January 29, 2019
‌ US Patent 9717735 Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferation	Patent 9717735 was granted and assigned to G1 Therapeutics on August, 2017 by the United States Patent and Trademark Office.	G1 Therapeutics	G1 Therapeutics	United States Patent and Trademark Office	9717735	August 1, 2017
‌ US Patent 10925878 HSPC-sparing treatments for RB-positive abnormal cellular proliferation	Patent 10925878 was granted and assigned to G1 Therapeutics on February, 2021 by the United States Patent and Trademark Office.	G1 Therapeutics	G1 Therapeutics	United States Patent and Trademark Office	10925878	February 23, 2021
‌ US Patent 9464092 Transient protection of normal cells during chemotherapy	Patent 9464092 was granted and assigned to G1 Therapeutics on October, 2016 by the United States Patent and Trademark Office.		G1 Therapeutics	United States Patent and Trademark Office	9464092	October 11, 2016
‌ US Patent 10189851 CDK inhibitors	Patent 10189851 was granted and assigned to G1 Therapeutics on January, 2019 by the United States Patent and Trademark Office.	G1 Therapeutics	G1 Therapeutics	United States Patent and Trademark Office	10189851	January 29, 2019
‌ US Patent 10966984 Transient protection of normal cells during chemotherapy	Patent 10966984 was granted and assigned to G1 Therapeutics on April, 2021 by the United States Patent and Trademark Office.	G1 Therapeutics	G1 Therapeutics	United States Patent and Trademark Office	10966984	April 6, 2021
‌ US Patent 10981887 Benzothiophene estrogen receptor modulators	Patent 10981887 was granted and assigned to G1 Therapeutics on April, 2021 by the United States Patent and Trademark Office.	G1 Therapeutics	G1 Therapeutics	United States Patent and Trademark Office	10981887	April 20, 2021
‌ US Patent 9499564 CDK inhibitors	Patent 9499564 was granted and assigned to G1 Therapeutics on November, 2016 by the United States Patent and Trademark Office.	G1 Therapeutics	G1 Therapeutics	United States Patent and Trademark Office	9499564	November 22, 2016
‌ US Patent 10633362 Benzothiophene estrogen receptor modulators		G1 Therapeutics	G1 Therapeutics	United States Patent and Trademark Office	10633362	April 28, 2020

Results per page:

32 results

0 selected

32 results

0 selected